MX375111B - Fenil acetato de l-ornitina y métodos para elaborar el mismo. - Google Patents

Fenil acetato de l-ornitina y métodos para elaborar el mismo.

Info

Publication number
MX375111B
MX375111B MX2018006692A MX2018006692A MX375111B MX 375111 B MX375111 B MX 375111B MX 2018006692 A MX2018006692 A MX 2018006692A MX 2018006692 A MX2018006692 A MX 2018006692A MX 375111 B MX375111 B MX 375111B
Authority
MX
Mexico
Prior art keywords
methods
phenyl acetate
ornithine phenyl
preparing same
forms
Prior art date
Application number
MX2018006692A
Other languages
English (en)
Inventor
Attilia Figini
Christine Henderson Dougan
Jim Behling
Keith Anderson
Peter Manini
Stephen William Watt
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX375111B publication Critical patent/MX375111B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas cristalinas de fenil acetato de L-ornitina y métodos para elaborar las mismas. La forma cristalina puede, en algunas modalidades, ser las formas I, II, II y V o mezclas de las mismas. Las formas cristalinas pueden ser formuladas para tratar sujetos con trastornos hepáticos, tales como encefalopatía hepática. Por consiguiente, algunas modalidades incluyen formulaciones y métodos para administrar fenil acetato de L-ornitina.
MX2018006692A 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y métodos para elaborar el mismo. MX375111B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16667609P 2009-04-03 2009-04-03
PCT/US2010/029708 WO2010115055A1 (en) 2009-04-03 2010-04-01 L-ornithine phenyl acetate and methods of making thereof

Publications (1)

Publication Number Publication Date
MX375111B true MX375111B (es) 2025-03-06

Family

ID=42828717

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014008993A MX356608B (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo.
MX2020009699A MX388894B (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo
MX2011010262A MX2011010262A (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo.
MX2018006692A MX375111B (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y métodos para elaborar el mismo.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2014008993A MX356608B (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo.
MX2020009699A MX388894B (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo
MX2011010262A MX2011010262A (es) 2009-04-03 2010-04-01 Fenil acetato de l-ornitina y metodos para elaborar el mismo.

Country Status (26)

Country Link
US (9) US8173706B2 (es)
EP (4) EP3686183B1 (es)
JP (6) JP6144488B2 (es)
KR (6) KR102399540B1 (es)
CN (3) CN104230730B (es)
AU (1) AU2010232521B2 (es)
BR (1) BRPI1013657A2 (es)
CA (5) CA2757373C (es)
CY (1) CY1119843T1 (es)
DK (3) DK2413924T3 (es)
EA (2) EA023051B1 (es)
ES (3) ES2652187T3 (es)
HR (2) HRP20171962T1 (es)
HU (2) HUE060371T2 (es)
IL (2) IL215449B (es)
LT (2) LT2413924T (es)
MX (4) MX356608B (es)
NO (1) NO2413924T3 (es)
NZ (3) NZ708458A (es)
PL (2) PL3686183T3 (es)
PT (2) PT3686183T (es)
SG (3) SG10201406300YA (es)
SI (1) SI2413924T1 (es)
SM (2) SMT201700601T1 (es)
WO (1) WO2010115055A1 (es)
ZA (1) ZA201107189B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN105481725B (zh) * 2014-09-18 2019-01-22 博瑞生物医药（苏州）股份有限公司 L-精氨酸苯乙酸盐的晶型及其制备方法
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
EP4205735A1 (en) * 2015-04-20 2023-07-05 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3352748A4 (en) * 2015-09-25 2019-06-05 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF NEURONAL CELL LOSS BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
SG11201802987UA (en) * 2015-11-13 2018-05-30 Ocera Therapeutics Inc Formulation of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN110740988A (zh) * 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
AU2020270106A1 (en) 2019-05-09 2021-11-18 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
CN110707221B (zh) * 2019-09-25 2023-09-01 北京大学深圳研究生院 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用
CN114786662A (zh) * 2019-10-16 2022-07-22 欧塞拉治疗有限公司 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
WO2023240081A1 (en) * 2022-06-06 2023-12-14 Yale University Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (es) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) * 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
JPH03273578A (ja) 1990-03-23 1991-12-04 Ricoh Co Ltd 対物レンズクリーニング装置
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (es) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
NZ255541A (en) 1992-09-09 1996-05-28 Fisons Plc Blister package for medicament-containing capsules with an aperture for dispensing the medicament; the package base has a sealing means to seal the capsule aperture
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
TWI309162B (en) 2001-03-15 2009-05-01 Rikagaku Kenkyusho Amino acid composition for improving functional disorder of liver
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
EP1541141A1 (en) 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) * 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7589235B2 (en) * 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
RS53324B (sr) 2005-11-17 2014-10-31 Silverstone Pharma Est. Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije
JPWO2007077995A1 (ja) 2006-01-05 2009-06-11 協和発酵バイオ株式会社 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
US20090306209A1 (en) 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
ES2652187T3 (es) * 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
SMT201800022T1 (it) 2012-11-21 2018-03-08 Horizon Therapeutics Llc Metodi per somministrare e valutare farmaci di rimozione dell'azoto per il trattamento di encefalopatia epatica
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
EP4205735A1 (en) 2015-04-20 2023-07-05 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3352748A4 (en) 2015-09-25 2019-06-05 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF NEURONAL CELL LOSS BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
AU2020270106A1 (en) 2019-05-09 2021-11-18 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
CN114786662A (zh) 2019-10-16 2022-07-22 欧塞拉治疗有限公司 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
AU2021277201A1 (en) 2020-05-22 2023-01-05 Ocera Therapeutics, Inc. Uses of ornithine phenylacetate for treating hyperammonemia

Also Published As

Publication number Publication date
JP2018138575A (ja) 2018-09-06
PT2413924T (pt) 2018-01-04
ES2928586T3 (es) 2022-11-21
EP3263100B1 (en) 2020-04-01
CA2998344C (en) 2020-06-02
KR101975726B1 (ko) 2019-05-07
MX2020009699A (es) 2021-12-17
EP3686183B1 (en) 2022-08-03
JP7086118B2 (ja) 2022-06-17
CA2998434C (en) 2020-05-12
CN102421432A (zh) 2012-04-18
ZA201107189B (en) 2012-12-27
KR20180033313A (ko) 2018-04-02
US20100280119A1 (en) 2010-11-04
CN106810464A (zh) 2017-06-09
CN102421432B (zh) 2014-09-17
SMT201700601T1 (it) 2018-03-08
PT3686183T (pt) 2022-10-03
PL2413924T3 (pl) 2018-02-28
AU2010232521A1 (en) 2011-11-17
DK2413924T3 (en) 2017-12-11
KR20210019592A (ko) 2021-02-22
US20150251990A1 (en) 2015-09-10
BRPI1013657A2 (pt) 2016-04-26
KR102217081B1 (ko) 2021-02-18
NO2413924T3 (es) 2018-02-24
IL215449A0 (en) 2011-12-29
SMT202200395T1 (it) 2022-11-18
EA201171216A1 (ru) 2012-05-30
EA034409B1 (ru) 2020-02-05
PL3686183T3 (pl) 2022-11-28
US9034925B2 (en) 2015-05-19
SG10201406300YA (en) 2015-01-29
US20180044281A1 (en) 2018-02-15
HUE035921T2 (en) 2018-05-28
LT3686183T (lt) 2022-11-10
US20200239406A1 (en) 2020-07-30
CN104230730A (zh) 2014-12-24
SG174982A1 (en) 2011-11-28
US11161802B2 (en) 2021-11-02
EA023051B1 (ru) 2016-04-29
KR20190068561A (ko) 2019-06-18
US20220162155A1 (en) 2022-05-26
EP2413924A4 (en) 2013-01-02
DK3263100T3 (da) 2020-05-11
CA2757373C (en) 2018-05-08
CA3077846A1 (en) 2010-10-07
US20140288327A1 (en) 2014-09-25
US9604909B2 (en) 2017-03-28
US12516015B2 (en) 2026-01-06
US20180319736A1 (en) 2018-11-08
US10550069B2 (en) 2020-02-04
MX2011010262A (es) 2012-01-25
CA3205755A1 (en) 2010-10-07
US8785498B2 (en) 2014-07-22
HRP20221232T8 (hr) 2023-02-03
HRP20171962T1 (hr) 2018-02-09
JP2015145372A (ja) 2015-08-13
MX356608B (es) 2018-06-06
KR20120006039A (ko) 2012-01-17
WO2010115055A1 (en) 2010-10-07
US10173964B2 (en) 2019-01-08
SI2413924T1 (en) 2018-01-31
JP6647336B2 (ja) 2020-02-14
EP3686183A1 (en) 2020-07-29
JP6010154B2 (ja) 2016-10-19
AU2010232521B2 (en) 2015-07-16
KR20220067001A (ko) 2022-05-24
CN104230730B (zh) 2017-05-24
CA2998434A1 (en) 2010-10-07
KR102399540B1 (ko) 2022-05-17
EP3263100A1 (en) 2018-01-03
CY1119843T1 (el) 2018-06-27
CA3077846C (en) 2023-08-22
CA2757373A1 (en) 2010-10-07
US8173706B2 (en) 2012-05-08
JP6144488B2 (ja) 2017-06-07
EP2413924A1 (en) 2012-02-08
IL215449B (en) 2019-01-31
JP6328737B2 (ja) 2018-05-23
KR101844605B1 (ko) 2018-04-02
US8492439B2 (en) 2013-07-23
MX388894B (es) 2025-03-20
ES2791524T3 (es) 2020-11-04
KR102123243B1 (ko) 2020-06-17
ES2652187T3 (es) 2018-01-31
JP2022088504A (ja) 2022-06-14
EP2413924B1 (en) 2017-09-27
EA201500650A1 (ru) 2015-10-30
NZ619235A (en) 2015-06-26
JP2012522803A (ja) 2012-09-27
HUE060371T2 (hu) 2023-02-28
HK1248558A1 (en) 2018-10-19
US20120208885A1 (en) 2012-08-16
DK3686183T3 (da) 2022-10-03
KR20200070438A (ko) 2020-06-17
LT2413924T (lt) 2018-02-12
SG10202010988WA (en) 2020-12-30
HRP20221232T1 (hr) 2022-12-23
CN106810464B (zh) 2019-01-22
US20130296429A1 (en) 2013-11-07
EP4101838A1 (en) 2022-12-14
IL263784A (en) 2019-01-31
CA2998344A1 (en) 2010-10-07
JP2020100624A (ja) 2020-07-02
NZ708458A (en) 2017-02-24
NZ595706A (en) 2014-01-31
JP2017081940A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
SG10201406300YA (en) L-ornithine phenyl acetate and methods of making thereof
BRPI0923702A2 (pt) composições de inseticida estáveis e métodos para produzir as mesmas
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
MX2012007164A (es) Composiciones para el cuidado oral.
WO2011127070A3 (en) IRE-1α INHIBITORS
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1116700T1 (el) Παρασκευη συνθετικου χολικου οξεος
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
BR112014009376A2 (pt) composições
IN2014DN07483A (es)
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
MX342947B (es) Tratamiento de diabetes tipo 2.
MX368876B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
BR112013007239A2 (pt) ''composição de chocolate aerado e processo para fabricação de uma composição de chocolate aerado''.
CL2011000073A1 (es) Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar.
MX2012007587A (es) Composiciones nutricionales que comprenden hojuelas de frutas que incluyen acido docosahexaenoico.